JP2006504710A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504710A5
JP2006504710A5 JP2004540788A JP2004540788A JP2006504710A5 JP 2006504710 A5 JP2006504710 A5 JP 2006504710A5 JP 2004540788 A JP2004540788 A JP 2004540788A JP 2004540788 A JP2004540788 A JP 2004540788A JP 2006504710 A5 JP2006504710 A5 JP 2006504710A5
Authority
JP
Japan
Prior art keywords
dibenz
azepine
carboxamide
dihydro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004540788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504710A (ja
Filing date
Publication date
Priority claimed from GBGB0223224.7A external-priority patent/GB0223224D0/en
Application filed filed Critical
Publication of JP2006504710A publication Critical patent/JP2006504710A/ja
Publication of JP2006504710A5 publication Critical patent/JP2006504710A5/ja
Pending legal-status Critical Current

Links

JP2004540788A 2002-10-07 2003-10-06 １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形 Pending JP2006504710A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en) 2002-10-07 2003-10-06 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (2)

Publication Number Publication Date
JP2006504710A JP2006504710A (ja) 2006-02-09
JP2006504710A5 true JP2006504710A5 (cg-RX-API-DMAC10.html) 2006-11-24

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540788A Pending JP2006504710A (ja) 2002-10-07 2003-10-06 １０，１１−ジヒドロ−１０−ヒドロキシ−５Ｈ−ジベンズ［ｂ，ｆ］アゼピン−５−カルボキサミドの両エナンチオマーのエナンチオ選択的製造方法およびその新規結晶形

Country Status (20)

Country Link
US (1) US20060142566A1 (cg-RX-API-DMAC10.html)
EP (1) EP1551808A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006504710A (cg-RX-API-DMAC10.html)
KR (1) KR20050071549A (cg-RX-API-DMAC10.html)
CN (2) CN101062932A (cg-RX-API-DMAC10.html)
AR (1) AR041544A1 (cg-RX-API-DMAC10.html)
AU (1) AU2003276055B2 (cg-RX-API-DMAC10.html)
BR (1) BR0315113A (cg-RX-API-DMAC10.html)
CA (1) CA2501237A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP055738A (cg-RX-API-DMAC10.html)
GB (1) GB0223224D0 (cg-RX-API-DMAC10.html)
HK (1) HK1079790A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05003737A (cg-RX-API-DMAC10.html)
NO (1) NO20052244L (cg-RX-API-DMAC10.html)
PE (1) PE20040686A1 (cg-RX-API-DMAC10.html)
PL (1) PL376379A1 (cg-RX-API-DMAC10.html)
RU (1) RU2005114350A (cg-RX-API-DMAC10.html)
TW (1) TW200413324A (cg-RX-API-DMAC10.html)
WO (1) WO2004031155A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200502561B (cg-RX-API-DMAC10.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) * 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
IN2015DN02296A (cg-RX-API-DMAC10.html) 2012-09-26 2015-08-21 Ranbaxy Lab Ltd
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9029540B2 (en) * 2013-07-01 2015-05-12 Boehringer Ingelheim International Gmbh Ruthenium catalysts and their use for asymmetric reduction of ketones
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN107207411A (zh) 2014-12-01 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
CA2374553A1 (fr) * 1999-06-15 2000-12-21 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
ES2211373T1 (es) * 2001-02-12 2004-07-16 Teva Pharmaceutical Industries Ltd. Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.

Similar Documents

Publication Publication Date Title
RU2005114350A (ru) Энантиоселективный способ получения обоих энантиомеров 10, 11-дигидро-10-гидрокси-5н-дибенз[b, f]азепин-5-карбоксамида и их новых кристаллических форм
TWI373470B (en) Process for preparing amino crotonyl compounds
RU2286988C2 (ru) Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
RU2007102228A (ru) Энантиоселективный способ получения производных хинолина
Herres‐Pawlis et al. A Library of Peralkylated Bis‐guanidine Ligands for Use in Biomimetic Coordination Chemistry
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
JPH10511114A (ja) 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド
JPH06510030A (ja) 新規な３，５−ジ−ｔｅｒｔ−ブチル−４−　ヒドロキシフェニル誘導体、それらの製造方法および薬剤
CZ20012959A3 (cs) Způsob výroby citalopramu
SU728713A3 (ru) Способ получени производных салициланилида
TW201735B (cg-RX-API-DMAC10.html)
WO2025138874A1 (zh) 可见光驱动合成2-芳基-2h-苯并三唑化合物的方法及其应用
Bera et al. Developing Supramolecular Metallogel Derived from Pd2L4 Cage Molecule for Delivering an Anti‐Cancer Drug to Melanoma Cell B16− F10
CN110845466B (zh) 氧杂环壬二烯衍生物、其药物组合物、其制备方法及用途
CA2239162A1 (en) Novel compounds with analgesic effect
TW200823207A (en) 4-nitrobenzoyl derivative having sulfoximine group and herbicide for rice
CN110156658A (zh) 一种含有取代二苯基和3-吲哚基骨架的手性(r)-三芳基甲烷衍生物及其合成方法
Tamura et al. Induction and inhibition of preferential enrichment by controlling the mode of the polymorphic transition with seed crystals
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途
KR101543667B1 (ko) 광학활성 2-아미노 트리아졸 유도체 및 이의 제조방법
Du et al. Hydroamination of Carbodiimides Catalyzed by Lithium Triethylborohydride
Kirschner et al. Anion Control of Lanthanoenediyne Cyclization
Braun et al. Bis (diphenylphosphino) acetonitrile oxides,-sulfides and-imines: Their formation and structural features, and the remarkable structures of two lithiated derivatives
CN113444107A (zh) 琥珀酰亚胺螺稠合磺内酰胺类化合物的合成方法及抗癌活性
JP6913692B2 (ja) オキサチアジン様化合物を作製する方法